key: cord-0920347-a6nbpta2
authors: Kreer, Christoph; Zehner, Matthias; Weber, Timm; Rohde, Cornelius; Halwe, Sandro; Ercanoglu, Meryem S.; Gieselmann, Lutz; Korenkov, Michael; Gruell, Henning; Schommers, Philipp; Vanshylla, Kanika; Di Cristanziano, Veronica; Janicki, Hanna; Brinker, Reinhild; Ashurov, Artem; Krähling, Verena; Kupke, Alexandra; Cohen-Dvashi, Hadas; Koch, Manuel; Lederer, Simone; Pfeifer, Nico; Wolf, Timo; Vehreschild, Maria J.G.T.; Wendtner, Clemens; Diskin, Ron; Becker, Stephan; Klein, Florian
title: Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
date: 2020-06-12
journal: bioRxiv
DOI: 10.1101/2020.06.12.146290
sha: d22f27d3c723e5120a6ec65646ca807a8ba0b5ca
doc_id: 920347
cord_uid: a6nbpta2

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and world economy. Since approved drugs and vaccines are not available, new options for COVID-19 treatment and prevention are highly demanded. To identify SARS-CoV-2 neutralizing antibodies, we analysed the antibody response of 12 COVID-19 patients from 8 to 69 days post diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days post diagnosis. Among these, 28 potently neutralized authentic SARS-CoV-2 (IC100 as low as 0.04 μg/ml), showing a broad spectrum of V genes and low levels of somatic mutations. Interestingly, potential precursors were identified in naïve B cell repertoires from 48 healthy individuals that were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2 neutralizing antibodies are readily generated from a diverse pool of precursors, fostering the hope of rapid induction of a protective immune response upon vaccination.

By mid-May 2020 over 4.5 million severe acute respiratory syndrome coronavirus 2 58 7 out of 28 neutralizing antibodies binding to the RBD, but only 31% of the non-157 neutralizing antibodies, suggesting that the RBD is a major site of vulnerability on the 158 S protein. Epitopes for non-neutralizing antibodies included the N-terminal S1 domain 159 and conformational epitopes ( Figure 3F, Table S4 ). Notably, both neutralizing and 160 non-neutralizing antibodies were characterized by a broad distribution of V H as well 161 as V L gene segments and a preference for κ light chains ( Figure 3G, Figure S4) . Figure S3 ). 166

Finally, we performed a HEp-2 cell autoreactivity assay. 4 out of 28 neutralizing 167 antibodies showed low to moderate signs of autoreactivity ( Figure S5 , Table S4 ) and 168 2 of them also reacted with other proteins (i.e. Ebola glycoprotein, HIV-1 gp140; 169 Table S4 ). In summary, these data show that SARS-CoV-2 neutralizing antibodies 170 develop from a broad set of different V genes and are characterized by a low degree 171 of somatic mutations. Moreover, we were able to isolate highly potent neutralizing 172 antibodies that present promising candidates for antibody mediated prevention and 173 therapy of SARS-CoV-2 infection. The low rate of somatic mutations in the majority of binding and neutralizing 198

and similar (± 1 aa in length and up to 3 aa differences) CDRH3s in 28 healthy 209 individuals ( Figure 5B and 4C) , including one exact CDRH3 match 210 (MnC2t1p1_C12). For light chains, we identified 1,357 κ chain precursors with exact 211 CDR3 matches that cover 41 of 62 antibodies and 109 λ chain precursors that 212 represent 7 of 17 antibodies (Figure 5B and 4C) . All 48 naive repertoires included at 213 least one κ and one λ chain precursor. When combining heavy and light chain data, 214

we found both precursor sequences of 9 antibodies in 14 healthy individuals ( Figure  215 5C). Importantly, among these potential precursor pairs, we found three potent 216 neutralizing antibodies (CnC2t1p1_B4, HbnC3t1p1_G4, and HbnC3t1p2_B10). While 217 the NGS repertoire data did not include pairing information of heavy and light chain 218 combinations, we found matched heavy and light chain sequences despite small 219 sample sizes of on average 9,500 heavy and 2,000 to 3,500 light chain clonotypes 220 per individual. We thus conclude that potential SARS-CoV-2 binding and neutralizing 221 antibody precursors are likely to be abundant in naïve B cell repertoires. antibodies against the RBD, truncated N-terminal S1 subunit (aa 14-529), and a 321 monomeric S ectodomain construct by ELISA. S2 binding was defined by interaction 322 with monomeric S but not RBD or S1. Antibodies interacting with none of the 323 subdomains were specified as conformational epitopes or not defined. (G) Top: 324

Frequencies of V H gene segments for non-neutralizing and neutralizing antibodies. For SPR measurement, the RBD was additionally purified by size exclusion 583 chromatography (SEC) purification with a Superdex200 10/300 column (GE 584

Healthcare). Binding of the RBD to the various mAbs was measured using single-585 cycle kinetics experiments with a Biacore T200 instrument (GE Healthcare). Purified 586 mAbs were first immobilized at coupling densities of 800-1200 response units (RU) 587 on a series S sensor chip protein A (GE Healthcare) in PBS and 0.02% sodium azide 588 buffer. One of the four flow cells on the sensor chip was empty to serve as a blank. 589 experimental data and to derive kinetic parameters. For some mAbs, a 1:1 binding 593 model did not provide an adequate description for binding. In these cases, we fitted a 594 two-state binding model that assumes two binding constants due to conformational 595 change. In these cases, we report the first binding constants (K D 1 ). 596 

Engineered Bispecific Antibodies with Exquisite HIV-1-661 Neutralizing Activity

Vaccine-Induced Antibodies that 664 Neutralize Group 1 and Group 2 Influenza A Viruses

Structure and Function 667 Analysis of an Antibody Recognizing All Influenza A Subtypes

Accelerating next-generation vaccine development for 670 global disease prevention. Science (80-. )

Optimized Sleeping Beauty transposons 672 rapidly generate stable transgenic cell lines

openPrimeR for multiplex amplification of 675 highly diverse templates

Exploiting B cell 677 receptor analyses to inform on HIV-1 vaccination strategies

Generation of stable monoclonal antibody-producing B cell receptor-positive human memory 681 B cells by genetic programming

The Role of Antibodies in HIV Vaccines

Passive immunotherapy of viral infections: "super-706 antibodies" enter the fray

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Longitudinal dynamics of the 712 human B cell response to the yellow fever 17D vaccine

Rational design of envelope identifies broadly neutralizing 719 human monoclonal antibodies to HIV-1

IgBLAST: an immunoglobulin variable 721 domain sequence analysis tool

A pneumonia outbreak associated with a new coronavirus of 724 probable bat origin